Cannabis Cash Is Bankrolling Anti-Legalization Republicans

September 15, 2026

Photo by Alexander Grey via Unsplash.

A super PAC that shares a treasurer with Donald Trump's own political operation is currently running ads for 11 vulnerable House Republicans, and a meaningful chunk of that money traces back to the cannabis industry. Trulieve, Curaleaf, Verano, Ascend Wellness and entities tied to Green Thumb Industries and AYR Wellness have collectively funneled millions into America First Agriculture Action Inc., which is now spending on behalf of GOP incumbents facing competitive 2026 races.

Here's the part that should make cannabis operators and consumers alike raise an eyebrow: several of those lawmakers have voted against federal legalization every chance they've had. That's not a rounding error or an oversight -- it's a pattern. So what exactly is the industry buying when it writes seven-figure checks to protect politicians who don't want to legalize the product these companies sell? The answer says a lot about where multistate operators think their leverage actually lies right now, and it isn't in the legalization fight most of their customers care about most.

How $11.5 Million Turned Into Ads for the GOP

Photo by cottonbro studio via Pexels.

The dollar figures here are worth sitting with. In June 2026, Trulieve, Curaleaf, Verano, Ascend Wellness, and entities connected to Green Thumb Industries and AYR Wellness combined to give $11.5 million to a group called America First Agriculture Action Inc. That single infusion pushed total cannabis-linked donations to Trump-connected political committees to at least $15.05 million, a figure that puts the industry squarely among the more active corporate donor blocs feeding into the current Republican political apparatus.

Of that pool, America First Agriculture Action is now spending close to $1.8 million on advertising supporting 11 House Republicans running in tight 2026 contests. That's a relatively small slice of the total haul, which raises its own questions about where the rest of the money is headed and how it might be deployed as the midterms approach.

Four companies did the heaviest lifting. Verano, Curaleaf, Trulieve, and Green Thumb's Vision Management Services subsidiary each wrote checks for exactly $2.5 million to the PAC -- a striking coincidence of round numbers that suggests some coordination, or at minimum a shared sense among these operators of what buy-in was expected. These are four of the largest multistate operators in the country, companies that already spend heavily on state-level lobbying and increasingly on federal influence campaigns tied to rescheduling and banking reform. Putting that kind of money behind a single Republican-aligned vehicle marks a notable escalation in how directly the industry is willing to play in federal electoral politics, rather than sticking to the trade-association lobbying that's defined most of its Washington presence to date.

Meet the 11 Lawmakers Getting the Support

Photo by Maxim Kapytka via Pexels.

The ad campaign is backing a specific list of Republicans, all of whom are staring down competitive November races: Tom Barrett of Michigan, Nick Begich of Alaska, Rob Bresnahan of Pennsylvania, Juan Ciscomani of Arizona, Gabe Evans of Colorado, Brian Fitzpatrick of Pennsylvania, Jen Kiggans of Virginia, Mike Lawler of New York, Scott Perry of Pennsylvania, Bryan Steil of Wisconsin, and Derrick Van Orden of Wisconsin. It's a mix of frontline suburban districts and swing seats where a few thousand votes could flip control.

What makes this list notable isn't just who's on it, but what several of these members have actually done on cannabis policy. Congress has held floor votes on federal legalization exactly twice -- in 2020 and again in 2022, both times under full Democratic control of the House. Fitzpatrick and Perry voted no both times, and they weren't outliers. Nearly every Republican present for those votes opposed legalization, reflecting a caucus-wide position that hasn't meaningfully shifted since.

So the industry is now spending real money to keep in office a group of lawmakers whose voting record runs directly counter to the industry's stated top legislative priority. That's not necessarily irrational, but it is a contradiction worth naming plainly: this isn't money aimed at expanding the coalition of pro-legalization votes in Congress. It's money aimed at something else entirely, and figuring out what that something else is requires looking at who's actually managing these funds.

The Treasurer Connecting All the Money

Photo by Jonathan Borba via Pexels.

Follow the paperwork and one name keeps showing up: Charles Gantt, who serves as treasurer for both America First Agriculture Action Inc. and MAGA Inc., Trump's own primary political committee. That shared treasurer role is the connective tissue linking cannabis industry money to Trump's broader political operation, even though the agriculture PAC's name gives no obvious hint of a cannabis connection.

The links run deeper. MAGA Inc. separately received $2.05 million from a group called American Rights and Reform PAC, which is itself backed by cannabis industry money. That same PAC gave $1.5 million to America First Agriculture Action last year, meaning cannabis dollars have been moving through multiple committees before landing in ads for House Republicans. The treasurer listed for American Rights and Reform PAC is Matt Harrell, a Curaleaf executive -- another direct thread tying a major multistate operator to the machinery funding these ads.

This isn't the industry's first foray into Trump-world giving, either. Trulieve and Curaleaf together contributed $1 million to Trump's 2024 inaugural committee, a now-familiar move for corporations looking to build relationships early in an administration.

Puck News reported that the ad spending was a reward tied to a hemp provision in a spending bill, framing it as payback for legislative help. That narrative has a problem: there was no standalone vote on that hemp provision, which makes it difficult to substantiate the reward theory as described. The money trail is real and well-documented. The precise motive behind the timing is murkier, and readers should be skeptical of any tidy explanation offered without a clear roll-call vote to point to.

Why an Industry Would Fund Its Opponents

The strategic logic starts to make more sense once you look at what's actually at stake in Washington right now. More than 20 Republican senators, along with several House members, have signed letters pressuring the White House to halt marijuana rescheduling -- the process that would move cannabis off Schedule I and unlock significant tax relief under IRS code 280E. That's an enormous financial prize for multistate operators, arguably bigger in the near term than full legalization itself.

Banking access tells a similar story. Getting cannabis businesses connected to normal financial services would solve immediate operational headaches that legalization alone wouldn't necessarily fix overnight. Increasingly, industry political strategy looks aimed at these narrower regulatory and tax wins rather than the harder, slower fight for comprehensive federal legalization.

Viewed that way, backing incumbents who oppose legalization isn't necessarily a betrayal of industry interests -- it might just be pragmatism. Whoever controls committee gavels and White House access matters more, in this framing, than any individual lawmaker's position on legalization itself. Access and influence with power, regardless of party or voting record, has its own value.

But that pragmatism comes at a cost. Forty states plus D.C. have legalized medical or recreational marijuana in some form since California started the trend in 1996, yet cannabis remains a Schedule I substance under the 1970 Controlled Substances Act, leaving federal policy stuck in place decades after most of the country moved on. This spending pattern exposes a widening gap between where industry donations flow and where the actual voter base -- which polls consistently show favors legalization by wide margins -- actually stands.

Add it all up and the picture that emerges isn't an industry fighting for legalization through the political system -- it's an industry playing insider access politics, betting that proximity to power pays off more reliably than ideological alignment. Multistate operators have the resources to hedge, and hedging by funding incumbents regardless of their cannabis voting record is exactly what this spending looks like.

The real test comes over the next year or two. If rescheduling actually moves forward, or if banking reform finally clears Congress, this investment will look shrewd in hindsight. If neither materializes and the money simply buys goodwill with lawmakers who keep voting no on legalization anyway, it'll be hard to see this as anything other than a very expensive relationship-maintenance exercise for companies with deep enough pockets to not need an immediate return.

Whatever happens in Washington, the practical reality on the ground hasn't changed: federal law still overrides these state-level dynamics, cannabis remains federally illegal regardless of who's funding whose campaign, and legality continues to vary widely from state to state. Anyone navigating this space -- as a consumer, patient, or businessperson -- should keep confirming their local rules rather than assuming national headlines translate into changes they can act on today.